ABG
RNAM

Ally Bridge Group’s Avidity Biosciences RNAM Stock Holding History

Ally Bridge Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132,744
Closed -$3.77M – 36
2025
Q2 		$3.77M Buy
+132,744
New +$3.96M 3.14% 15

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ally Bridge Group's RNAM Position: Q3 2025 in Review

Ally Bridge Group sold out of Avidity Biosciences (RNAM) in Q3 2025, closing a stake of 132,744 shares — an estimated $3.77M sold.

Ally Bridge Group first reported a position in RNAM in Q2 2025 and held it in 1 quarter. The position peaked at $3.77M in Q2 2025. 272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • Ally Bridge Group reported no remaining Avidity Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ally Bridge Group sold 132,744 Avidity Biosciences shares in Q3 2025, an estimated $3.77M.
  • Ally Bridge Group first reported a position in Avidity Biosciences in Q2 2025 and held it in 1 quarter.
  • Ally Bridge Group's Avidity Biosciences position peaked at $3.77M in Q2 2025.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on Ally Bridge Group's 13F filing for Q3 2025, filed 14 Nov 2025.